Benzinga | May 26, 2021 07:41AM EDT

Wedbush Downgrades Travere Therapeutics to Neutral, Announces $19 Price Target

Wedbush analyst Laura Chico downgrades Travere Therapeutics (NASDAQ:TVTX) from Outperform to Neutral and announces $19 price target.